¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå : Áúȯº°, À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - ¼¼°è »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Viral Vector Vaccines Market, By Disease, By Type, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå
:
1781961
¸®¼Ä¡»ç
:
AnalystView Market Insights
¹ßÇàÀÏ
:
2025³â 06¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 269 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
º¸°í¼ ÇÏÀ̶óÀÌÆ®
¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 8¾ï 5,043¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2025-2032³â¿¡ CAGR 15.93%·Î È®´ë
¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - ½ÃÀå ¿ªÇÐ
Àü¿°º´ È®»ê Áõ°¡·Î ½ÃÀå ¼ö¿ä Áõ°¡
COVID-19, µ¶°¨, °£¿° µî °¨¿°¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡·Î È¿°úÀûÀÎ ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¹é½ÅÀº ¿¬°£ 200¸¸-300¸¸ ¸íÀÇ »ç¸ÁÀ» ¿¹¹æÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°è º¸°Ç¿¡¼ ¹é½ÅÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯Àü°øÇÐÀÇ ²÷ÀÓ¾ø´Â ¹ßÀüÀº º¸´Ù È¿À²ÀûÀÎ ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½ÅÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª µå¹°Áö¸¸ ºÎÀÛ¿ëÀÌ º¸°íµÇ°í ÀÖÀ¸¸ç, ÀϹÝÀεéÀÌ ÁÖÀúÇϰí ÀÖÀ¸¸ç, ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇÑÆí, °³¹ßµµ»ó±¹Àº ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±°ú ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.
¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®
´ç»çÀÇ ¸®¼Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 15.93%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Áúȯº°·Î´Â °¨¿°¼º ÁúȯÀÌ 2024³â °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» º¸¿´½À´Ï´Ù.
À¯Çüº°·Î´Â ¾Æµ¥³ë¹ÙÀÌ·¯½º°¡ 2024³â ÁÖ¿ä À¯ÇüÀÔ´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâ 1À§¸¦ ±â·ÏÇß½À´Ï´Ù.
¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - ¼¼ºÐÈ ºÐ¼®
¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ¼¼°è ½ÃÀåÀº Áúº´, À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.
Áúȯº°·Î´Â °¨¿°¼º Áúȯ, ¾Ï, À¯Àü¼º Áúȯ, ±âŸ 4°¡Áö·Î ºÐ·ùµË´Ï´Ù. °¨¿°¼º Áúȯ ºÎ¹®Àº ¿¹Ãø ±â°£ Áß ¼¼°è ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå¿¡¼ ÁÖ¿ä ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ÁÖ·Î Àü ¼¼°è °¨¿°º´ÀÇ ºÎ´ãÀÌ Å©°í, ¹ÙÀÌ·¯½º º¤ÅÍ Ç÷§ÆûÀÌ °¨¿°º´¿¡ ´ëÇÑ ¹é½Å °³¹ß¿¡¼ ÀÔÁõµÈ È¿°ú¿¡ ±âÀÎÇÕ´Ï´Ù.
½ÃÀåÀº ¾Æµ¥³ë ¼ö¹Ý ¹ÙÀÌ·¯½º(AAV), ¾Æµ¥³ë ¹ÙÀÌ·¯½º, ·»Ä¡ ¹ÙÀÌ·¯½º, ·¹Æ®·Î ¹ÙÀÌ·¯½º, ±âŸ 5°¡Áö Ä«Å×°í¸®·Î ³ª´¹´Ï´Ù. ¿¹Ãø ±â°£ Áß ¾Æµ¥³ë¹ÙÀÌ·¯½º ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â ÁÖ·Î ¾Æµ¥³ë¹ÙÀÌ·¯½º°¡ °ÇÑ ¸é¿ª¿ø¼º, Å« À¯ÀüÀÚ ÆäÀ̷ε带 ¿î¹ÝÇÏ´Â ´É·Â, ½Å¼ÓÇÑ ¹é½Å °³¹ß¿¡ ÀûÇÕÇϹǷΠ³Î¸® »ç¿ëµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.
¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®
ºÏ¹Ì°¡ Àü ¼¼°è ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â ÷´ÜÀÎ ÇコÄɾî ÀÎÇÁ¶ó, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, ÁÖ¿ä Á¦¾à»ç ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ Á¸Àç¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÇコÄɾî ÅõÀÚ Áõ°¡, °¨¿°º´ À¯Çà Áõ°¡, ÷´Ü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ ¼¼°è ½ÃÀå¿¡¼ °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - °æÀï ±¸µµ
È¿°úÀûÀ̰í Áï°¢ÀûÀÎ ¹é½Å¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ¼ö¿ä Áõ°¡´Â ±â¼ú Çõ½Å°ú Àü·«Àû ÅõÀÚÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±â¾÷Àº ±ÞÁõÇÏ´Â ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ º¤ÅÍ ¼³°è °È, ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ °³¼±, Á¦Á¶ ´É·Â È®´ë¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü ¹× Á¤ºÎ±â°ü°úÀÇ Á¦ÈÞ´Â °³¹ß ¹× ÀǾàǰ Çã°¡¸¦ °¡¼ÓÈÇϱâ À§ÇØ ÀϹÝÀûÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï °¨¿°º´ ¹é½Å µî °¢»ç´Â Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀ» ´Ù¾çÈÇϰí ÀÖ½À´Ï´Ù. ¼¼°è ÀÔÁö¸¦ °ÈÇϰí ÷´Ü ¹é½Å Ç÷§Æû¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̱â À§ÇØ Áö¿ªÀû È®Àå ¹× Àμö¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå °³¿ä
Á¦2Àå °³¿ä
Á¦3Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½ÅÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ±âȸ
½ÃÀåÀÇ ÇâÈÄ µ¿Çâ
Á¦4Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å »ê¾÷ ¿¬±¸
PEST ºÐ¼®
Porter's Five Forces ºÐ¼®
¼ºÀå Àü¸Á ÁöµµÁ¦ÀÛ
±ÔÁ¦ ±¸Á¶ ºÐ¼®
Á¦5Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ
COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ
·¯½Ã¾Æ¡¤¿ìÅ©¶óÀ̳ª ÀüÀïÀÇ ¿µÇâ
Áßµ¿ ºÐÀïÀÇ ¿µÇâ
Á¦6Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå ±¸µµ
¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
ÁÖ¿ä Á¦Á¶¾÷üº° ³»¿ª µ¥ÀÌÅÍ
±âÁ¸ ±â¾÷ÀÇ ºÐ¼®
½Å±Ô ±â¾÷ÀÇ ºÐ¼®
Á¦7Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - Áúȯº°
°³¿ä
Áúȯº° ºÎ¹® Á¡À¯À² ºÐ¼®
°¨¿°Áõ
¾Ï
À¯Àü¼º Áúȯ
±âŸ
Á¦8Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - À¯Çüº°
°³¿ä
À¯Çüº° ºÎ¹® Á¡À¯À² ºÐ¼®
¾Æµ¥³ë¿¬°ü¹ÙÀÌ·¯½º(AAV)
¾Æµ¥³ë¹ÙÀÌ·¯½º
·»Æ¼¹ÙÀÌ·¯½º
·¹Æ®·Î¹ÙÀÌ·¯½º
±âŸ
Á¦9Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°
°³¿ä
ÃÖÁ¾»ç¿ëÀÚº° ºÎ¹® Á¡À¯À² ºÐ¼®
Á¦¾àȸ»ç¿Í ¹ÙÀÌ¿ÀÀǾàǰ ȸ»ç
¿¬±¸±â°ü
Á¦10Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å ½ÃÀå - Áö¿ª
¼·Ð
ºÏ¹Ì
°³¿ä
ºÏ¹ÌÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
¹Ì±¹
ij³ª´Ù
À¯·´
°³¿ä
À¯·´ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
µ¶ÀÏ
¿µ±¹
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
³×´ú¶õµå
½º¿þµ§
·¯½Ã¾Æ
Æú¶õµå
±âŸ
¾Æ½Ã¾ÆÅÂÆò¾ç
°³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
Áß±¹
Àεµ
ÀϺ»
Çѱ¹
È£ÁÖ
Àεµ³×½Ã¾Æ
ű¹
Çʸ®ÇÉ
±âŸ
¶óƾ¾Æ¸Þ¸®Ä«
°³¿ä
¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
ºê¶óÁú
¸ß½ÃÄÚ
¾Æ¸£ÇîÆ¼³ª
ÄÝ·Òºñ¾Æ
±âŸ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°³¿ä
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
À̽º¶ó¿¤
Æ¢¸£Å°¿¹
¾ËÁ¦¸®
ÀÌÁýÆ®
±âŸ
Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¹ÙÀÌ·¯½º º¤ÅÍ ¹é½Å »ê¾÷
°æÀï ´ë½Ãº¸µå
°æÀï º¥Ä¡¸¶Å·
°æÀï Æ÷Áö¼Å´×
±â¾÷ °³¿ä
Advanced Bioscience Laboratories
Sanofi SA
CH Boehringer Sohn AG & Ko
Brammer Bio, LLC
GE Healthcare
Creative Biogene
Pfizer Inc.
Moderna Inc.
Sinovac BIoTech Ltd.
CSL Ltd.
Astra Zeneca plc
GSK plc
Serum Institute of India Pvt. Ltd.
Merck & Co. Inc.
Novasep
Charles River Laboratories
Waisman Biomanufacturing
uniQure NV
Creative-Biogene
Addgene
Aldevron
Thermo Fisher Scientific Inc.
Spark Therapeutics Inc.
±âŸ
Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§Àû Àü¸Á
KSA
¿µ¹® ¸ñÂ÷
REPORT HIGHLIGHT
Viral vector vaccines market size was valued at US$ 850.43 Million in 2024, expanding at a CAGR of 15.93% from 2025 to 2032.
Viral vector vaccines use a harmless virus as a delivery system to introduce genetic material from a pathogen into the body. This genetic code instructs cells to produce a protein that triggers an immune response without causing disease. These vaccines mimic natural infection, training the immune system to recognize and fight the real virus if exposed later. They are widely used in preventing infectious diseases like COVID-19 and Ebola.
Viral Vector Vaccines Market- Market Dynamics
Increasing prevalence of infectious diseases to propel market demand
The rising incidence of infectious diseases such as COVID-19, influenza, and hepatitis is propelling the demand for effective vaccines. According to the World Health Organization (WHO), vaccines prevent 2 to 3 million deaths annually, highlighting their critical role in global health. In addition, continuous progress in genetic engineering has facilitated the development of more efficient viral vector vaccines. However, instances of adverse effects, although rare, have been reported, leading to public hesitance, which is predicted to hamper the market growth in the coming years. On the contrary, developing regions present significant growth opportunities due to improving healthcare infrastructure and rising awareness about vaccination.
Viral Vector Vaccines Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.93% over the forecast period (2025-2032)
Based on Disease segmentation, infectious diseases was predicted to show maximum market share in the year 2024
Based on Type segmentation, adenovirus was the leading Type in 2024
On the basis of region, North America was the leading revenue generator in 2024
Viral Vector Vaccines Market- Segmentation Analysis:
The Global Viral Vector Vaccines Market is segmented on the basis of Disease, Type, End User, and Region.
The market is divided into four categories based on Disease: infectious diseases, cancer, genetic disorders, and others. The infectious diseases segment is expected to hold the major market share in the global viral vector vaccines market during the forecast period. This dominance is primarily driven by the high global burden of infectious diseases and the proven effectiveness of viral vector platforms in developing vaccines against them.
The market is divided into five categories based on Type: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, and others. The adenovirus segment is expected to account for the largest market share during the forecast period. This is mainly because adenoviruses are widely used due to their strong immunogenicity, ability to carry large genetic payloads, and suitability for rapid vaccine development.
Viral Vector Vaccines Market- Geographical Insights
The North America region holds the largest share of the global viral vector vaccines market. This dominance is attributed to its advanced healthcare infrastructure, substantial investments in research and development, and the presence of leading pharmaceutical and biotechnology companies. Besides, the Asia-Pacific region is projected to experience the fastest growth in the global market, driven by the increasing healthcare investments, a rising prevalence of infectious diseases, and growing awareness of advanced therapeutic options.
Viral Vector Vaccines Market- Competitive Landscape:
Rising global demand for effective and rapid-response vaccines is driving technological innovation and strategic investment. Companies are focusing on enhancing vector design, improving safety profiles, and expanding manufacturing capabilities to meet surging demand. Partnerships with research institutions and government bodies are common to accelerate development and regulatory approval. Additionally, players are diversifying product pipelines to include vaccines for emerging infectious diseases. Regional expansions and acquisitions are also being pursued to strengthen global presence and increase access to advanced vaccine platforms.
Recent Developments:
In June 2025, ImmunoPrecise Antibodies Ltd. identified a stable epitope common to all four dengue virus serotypes using its AI-powered LENSai(TM) platform. This breakthrough supports progress toward a universal dengue vaccine using epitope-based targeting.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL VIRAL VECTOR VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Advanced Bioscience Laboratories
Sanofi S.A.
C.H. Boehringer Sohn AG & Ko
Brammer Bio, LLC
GE Healthcare
Creative Biogene
Pfizer Inc.
Moderna Inc.
Sinovac Biotech Ltd.
CSL Ltd.
Astra Zeneca plc
GSK plc
Serum Institute of India Pvt. Ltd.
Merck & Co. Inc.
Novasep
Charles River Laboratories
Waisman Biomanufacturing
uniQure N.V.
Creative-Biogene
Addgene
Aldevron
Thermo Fisher Scientific Inc.
Spark Therapeutics Inc.
Others
GLOBAL VIRAL VECTOR VACCINES MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032
Infectious Diseases
Cancer
Genetic Disorders
Others
GLOBAL VIRAL VECTOR VACCINES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032
Adeno-associated virus (AAV)
Adenovirus
Lentivirus
Retrovirus
Others
GLOBAL VIRAL VECTOR VACCINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
Pharmaceutical and Biopharmaceutical Companies
Research Institutes
GLOBAL VIRAL VECTOR VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA
Table of Contents
1. Viral Vector Vaccines Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Viral Vector Vaccines Market Snippet by Disease
2.1.2. Viral Vector Vaccines Market Snippet by Type
2.1.3. Viral Vector Vaccines Market Snippet by End User
2.1.4. Viral Vector Vaccines Market Snippet by Country
2.1.5. Viral Vector Vaccines Market Snippet by Region
2.2. Competitive Insights
3. Viral Vector Vaccines Key Market Trends
3.1. Viral Vector Vaccines Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Viral Vector Vaccines Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Viral Vector Vaccines Market Opportunities
3.4. Viral Vector Vaccines Market Future Trends
4. Viral Vector Vaccines Industry Study
4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Viral Vector Vaccines Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Viral Vector Vaccines Market Landscape
6.1. Viral Vector Vaccines Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players' Analysis
6.2.2. Emerging Players' Analysis
7. Viral Vector Vaccines Market - By Disease
7.1. Overview
7.1.1. Segment Share Analysis, By Disease, 2024 & 2032 (%)
7.1.2. Infectious Diseases
7.1.3. Cancer
7.1.4. Genetic Disorders
7.1.5. Others
8. Viral Vector Vaccines Market - By Type
8.1. Overview
8.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
8.1.2. Adeno-associated virus (AAV)
8.1.3. Adenovirus
8.1.4. Lentivirus
8.1.5. Retrovirus
8.1.6. Others
9. Viral Vector Vaccines Market - By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
9.1.2. Pharmaceutical and Biopharmaceutical Companies
9.1.3. Research Institutes
10. Viral Vector Vaccines Market- By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Viral Vector Vaccines Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Viral Vector Vaccines Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.9.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3.16. Rest of Europe
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.16.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.16.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Viral Vector Vaccines Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.7.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.8.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Viral Vector Vaccines Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Viral Vector Vaccines Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.6. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Viral Vector Vaccines Industry
11.1. Competitive Dashboard
11.1.1. Competitive Benchmarking
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Advanced Bioscience Laboratories
11.2.2. Sanofi S.A.
11.2.3. C.H. Boehringer Sohn AG & Ko
11.2.4. Brammer Bio, LLC
11.2.5. GE Healthcare
11.2.6. Creative Biogene
11.2.7. Pfizer Inc.
11.2.8. Moderna Inc.
11.2.9. Sinovac Biotech Ltd.
11.2.10. CSL Ltd.
11.2.11. Astra Zeneca plc
11.2.12. GSK plc
11.2.13. Serum Institute of India Pvt. Ltd.
11.2.14. Merck & Co. Inc.
11.2.15. Novasep
11.2.16. Charles River Laboratories
11.2.17. Waisman Biomanufacturing
11.2.18. uniQure N.V.
11.2.19. Creative-Biogene
11.2.20. Addgene
11.2.21. Aldevron
11.2.22. Thermo Fisher Scientific Inc.
11.2.23. Spark Therapeutics Inc.
11.2.24. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
°ü·ÃÀÚ·á